Mirtazapina Aurovitas Spain (Mirtazapine)

Mirtazapine works by blocking central presynaptic alpha‑2 adrenergic receptors, which increases the release of norepinephrine. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 serotonin receptors and H1 histamine receptors, leading to enhanced serotonergic and noradrenergic neurotransmission that contributes to its antidepressant effect.

The dose of mirtazapine is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the starting dose, any titration steps, and the maintenance dose, following local prescribing guidelines and product labeling.

Safety data for mirtazapine in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing women.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirtazapine belongs to the NaSSA class, whereas many alternatives such as SSRIs primarily inhibit serotonin reuptake. Mirtazapine often causes sedation and weight gain, which can be advantageous for patients with insomnia or appetite loss, but these effects differ from the more activating profile of typical SSRIs.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct light, and ensure they are out of reach of children. No special refrigeration is required.

The medication is taken orally as a tablet. It can be swallowed with or without food, although taking it with a light snack may reduce the intensity of sedation for some patients. Follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious risks include agranulocytosis or severe neutropenia, seizures, significant weight gain, and the emergence or worsening of suicidal thoughts, especially early in therapy. Rarely, severe hypersensitivity reactions or cardiac arrhythmias such as QT prolongation may occur, requiring prompt medical attention.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with a history of bipolar disorder or uncontrolled seizures.